Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. (OTCQB: AINMF) generates news centered on the application of explainable artificial intelligence to pharmaceutical clinical trials. The company regularly reports on contracts with global pharmaceutical and biopharmaceutical companies, collaborations with research institutions, scientific publications, and regulatory-science interactions related to its NetraAI platform.
News updates often highlight new agreements in which NetraAI is applied to late-stage clinical studies, including Phase III trials in psychiatric indications. These announcements describe how NetraAI is used to identify responder and non-responder subgroups, analyze treatment and placebo-response patterns, and support interpretation of complex trial outcomes. The company also reports on expansions of existing relationships through master services agreements and the growth of its contract backlog for NetraAI services.
Another recurring theme in NetraMark’s news is its scientific and academic engagement. The company has announced acceptance of a peer-reviewed NetraAI study in npj Digital Medicine, presentations at CNS-focused clinical trial and neuropsychopharmacology conferences, and research collaborations in areas such as major depressive disorder, schizophrenia, and glioblastoma. These items describe how NetraAI is deployed within secure research environments to analyze clinical, genetic, epigenetic, and proteomic datasets and to uncover explainable patient subpopulations.
Regulatory-science news includes coverage of NetraMark’s Critical Path Innovation Meeting with the U.S. Food and Drug Administration, where the scientific aspects of NetraAI’s enrichment methodology were discussed. Financing news, such as private placement offerings, provides context on how the company plans to fund advancement and commercialization of NetraAI and support ongoing and prospective biopharmaceutical engagements.
Investors and observers who follow AINMF news can therefore expect updates on commercial contracts, research collaborations, peer-reviewed publications, regulatory-science interactions, and capital-raising activities, all tied to the development and deployment of NetraAI in pharmaceutical clinical development.
NetraMark Holdings (OTCQB: AINMF), an AI company specializing in clinical trial optimization, has appointed Dr. Jan Sedway as Senior Vice President of Clinical Science. Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations, previously serving as Vice President of Clinical Development at Clario.
The appointment aligns with NetraMark's strategic expansion in the pharmaceutical industry, focusing on scaling its AI-powered solutions across psychiatry, oncology, and other therapeutic areas. Dr. Sedway's experience includes advancing digital biomarker solutions and driving operational excellence in global clinical trials, with previous leadership roles at Parexel and Syneos Health.
NetraMark Holdings (OTCQB: AINMF) has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform for analyzing results from a pivotal Phase III pediatric clinical trial. The study, CIT-003-01, evaluates the efficacy of intravenous L-citrulline in preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.
NetraAI's technology will utilize explainable AI and generative modeling to optimize trial outcomes through enhanced patient stratification and identification of responder personas. The partnership aims to demonstrate L-citrulline's benefits in specific patient subgroups and inform future study designs.
NetraMark Holdings (OTCQB: AINMF), an AI company focused on clinical trials transformation, announced its CEO George Achilleos will attend Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.
The company's platform, NetraAI, is designed to enhance clinical development by identifying explainable patient subpopulations, uncovering drug response drivers, reducing placebo effects, and improving patient selection strategies. During the conference, the CEO will be available for one-on-one meetings with institutional investors, pharmaceutical sponsors, and strategic partners to discuss the platform's applications across therapeutic areas.
NetraMark Holdings (OTCQB: AINMF) has partnered with Pentara Corporation to launch an AI-powered site intelligence tool for enhancing clinical trial integrity. The collaboration introduces a novel system that calculates a Paradox Risk score to detect anomalous participant behavior and site-level irregularities using pre-randomization data.
The partnership combines NetraMark's AI technology with Pentara's expertise in clinical data analysis, particularly in degenerative diseases. The tool integrates information-theoretic variability, singleton occurrence frequencies, and co-association penalties to identify potential data integrity issues that could affect trial outcomes.
This strategic alliance aims to enable proactive risk mitigation, implement scalable site monitoring with real-time alerts, and enhance confidence in efficacy outcomes across heterogeneous clinical trials.
NetraMark Holdings (OTCQB: AINMF) has entered into an agreement with AlgoTherapeutix (AlgoTx) to enhance clinical trial design for ATX01, a treatment for chemotherapy-induced peripheral neuropathy (CIPN). NetraMark will deploy its NetraAI platform to analyze patient-level data from the ATX01 program.
The collaboration aims to leverage NetraAI's unique technology to identify responder personas, explore drug and placebo response variables, and develop enrichment strategies for future trials. The partnership will focus on creating customized AI models and interactive tools that enable hypothesis testing and precise characterization of patient subpopulations, with the goal of generating validated, explainable insights for regulatory submission.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), an AI company specializing in clinical trials analytics, has announced a shareholder conference call scheduled for Tuesday, April 15, 2025, from 4:00-4:30pm EST. CEO George Achilleos will lead the discussion on recent developments and growth strategies.
Key highlights include a strategic partnership with Worldwide Clinical Trials, which is integrating NetraAI into various clinical trials, particularly in neuroscience and oncology. The company will discuss its regulatory alignment strategy, focusing on how its explainable AI capabilities support clinical trials and FDA submissions.
The call will also showcase NetraAI's technological differentiation, highlighting its ability to identify subpopulations in small datasets and reduce overfitting. Additionally, NetraMark has extended its agreement with 1502656 B.C for public relations services, with additional compensation of $200,000 CDN for a six-month term.
NetraMark Holdings (OTCQB: AINMF) has announced a global partnership with Worldwide Clinical Trials to enhance clinical trial design using AI technology. The collaboration integrates NetraMark's proprietary NetraAI platform into Worldwide's service offerings, initially focusing on Phase 2 neuroscience and oncology trials, with plans to expand across all therapeutic areas.
The partnership combines Worldwide's three decades of clinical execution excellence and 11 consecutive CRO Leadership Awards with NetraMark's advanced AI solution. The integration aims to optimize clinical trials by identifying hidden patient subpopulations within complex datasets, improving trial efficiency, and delivering regulatory-aligned insights.
Key benefits include accelerated development timelines, refined patient stratification, reduced placebo response variability, and enhanced trial power. The collaboration is expected to enable more informed protocol development, faster decision-making, and improved patient targeting, ultimately leading to fewer required patients per trial, reduced timelines, and lower costs for sponsors.